Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Enforcement Directorate (ED)
ITR Deadline
Coronavirus India
Coronavirus Cases In India
Money Laundering Case
Sidhu Moose Wala
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial
India

Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial

Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial
Written by Astha Oriel
(Sourced from PTI)
Jan 20, 2021, 02:35 pm 2 min read
Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial

An expert panel, Central Drugs Standard Control Organisation, (CDSCO) on Tuesday recommended granting permission for conducting the Phase I clinical trial of an intranasal vaccine against COVID-19 developed by Bharat Biotech, official sources said. VK Paul, NITI Aayog member (Health) said, "If this vaccine works, it can be a game-changer because it is so easy to use and we look forward to this development."

Details
Bharat Biotech applied to DCGI for permission to conduct trial

Bharat Biotech had applied to the Drugs Controller General of India seeking permission for conducting Phase I and Phase II clinical trials of the intranasal vaccine, following which the expert committee recommended granting permission. "Based on the safety and immunogenicity data of Phase I clinical trial, the company would be given permission for conducting Phase II clinical trial," an official said.

Quote
'Intranasal COVID-19 vaccine preclinical testing has been completed'

"BBV154 (intranasal COVID-19 vaccine) preclinical testing has been completed for toxicology, immunogenicity, and challenge studies. These studies have been conducted in the USA and India. Phase I human clinical trials will commence during February-March 2021," the vaccine maker said.

NITI Aayog's statement
A nasal vaccine candidate has been identified: Dr. Paul

Dr. Paul had earlier informed, "A nasal vaccine candidate has been identified. It has come for consideration to the drug regulator for Phase I and Phase II clinical trials." "It looks like an exciting development because potentially, this route can be used to deliver the safe antigen against which an immunological response would happen," Dr. Paul added.

Bharat Biotech's statement
'One drop of vaccine in each nostril is sufficient'

Dr. Krishna Ella, the Chairman of Bharat Biotech, had earlier said that the company is focusing on the intranasal vaccine as existing vaccines require two-dose intramuscular injections and a country like India needs 2.6 billion syringes and needles which may add to pollution. "One drop of vaccine in each of the nostrils is sufficient," he had said.

Information
How will the intranasal vaccine work?

Dr. Ella said that an intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Astha Oriel <br/><i>(Sourced from PTI)</i>
Astha Oriel
(Sourced from PTI)
Twitter
I am a graduate of the Indian Institute of Journalism and New Media, Bangalore. As a history buff, I am an avid reader. When I am not reading, I like to listen to classical Hollywood and Bollywood songs, learn a new language, or doodle.
Latest
Central Drugs Standard Control Organization (CDSCO)
Drugs Controller General of India
Coronavirus
Bharat Biotech
Related
Latest
Sensex climbs to 58,853 points, Nifty settles at 17,525
Sensex climbs to 58,853 points, Nifty settles at 17,525 Business
'Sita Ramam,' 'Bimbisara,' 'Bullet Train': Analyzing Weekend-1 box office collections
'Sita Ramam,' 'Bimbisara,' 'Bullet Train': Analyzing Weekend-1 box office collections Entertainment
3-year-old in coma after father beats her for playing longer
3-year-old in coma after father beats her for playing longer India
Infinix Hot 12 Pro now available: Check pricing
Infinix Hot 12 Pro now available: Check pricing Technology
#DealOfTheDay: Xiaomi 12 Pro gets discounts up to Rs. 13,250
#DealOfTheDay: Xiaomi 12 Pro gets discounts up to Rs. 13,250 Technology
Central Drugs Standard Control Organization (CDSCO)
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon India
J&J withdraws vaccine approval request in India, CDSCO says
J&J withdraws vaccine approval request in India, CDSCO says India
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN India
Expert panel says no to Covovax's children trials in India
Expert panel says no to Covovax's children trials in India India
COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel
COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel India
More News
Drugs Controller General of India
Clinical trials for nasal COVID-19 vaccine complete: Bharat Biotech
Clinical trials for nasal COVID-19 vaccine complete: Bharat Biotech India
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years India
COVAXIN likely to get approval for children above 2yrs: Report
COVAXIN likely to get approval for children above 2yrs: Report India
Biological E's Corbevax vaccine approved for children aged 12-18 years
Biological E's Corbevax vaccine approved for children aged 12-18 years India
COVAXIN, Covishield will now be available in hospitals and clinics
COVAXIN, Covishield will now be available in hospitals and clinics India
More News
Coronavirus
How long does immunity last after COVID-19?
How long does immunity last after COVID-19? Technology
#NewsBytesExplainer: Why experts believe 4th COVID-19 wave is not coming
#NewsBytesExplainer: Why experts believe 4th COVID-19 wave is not coming India
COVID-19: India logs 7,584 fresh cases, 24 more fatalities
COVID-19: India logs 7,584 fresh cases, 24 more fatalities India
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
More News
Bharat Biotech
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension India
COVAXIN supply to be increased as teens get COVID-19 vaccines
COVAXIN supply to be increased as teens get COVID-19 vaccines India
Are Indian vaccines effective against Omicron? Here's what manufacturers say
Are Indian vaccines effective against Omicron? Here's what manufacturers say India
COVAXIN gets WHO approval for emergency use listing
COVAXIN gets WHO approval for emergency use listing India
Australia accepts COVAXIN as 'recognized' vaccine for incoming travelers
Australia accepts COVAXIN as 'recognized' vaccine for incoming travelers World
More News
Related
Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
Expert panel recommends emergency use authorization for Zydus's three-dose vaccine India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022